Collaborative Trajectory Analysis Project - Crunchbase Company Profile & Funding

Overview

Collaborative Trajectory Analysis Project

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Collaborative Trajectory Analysis Project

CB Rank

621448

Enabling leading clinical experts to solve critical problems in Duchenne drug development

Founded

obfuscation

Private

Cambridge, Massachusetts, United States

ctap-duchenne.org

Biotechnology

Health Care

Key People

Susan Ward: Founder and Executive Director

Details

Operating Status

Active

Company Type

For Profit

Founders

Susan Ward

About the Company

Enabling leading clinical experts to solve critical problems in Duchenne drug development. The cTAP team is an unprecedented coalition of leaders bound together by common purpose and mutual respect, creativity in overcoming traditional barriers, and an unrelenting sense of urgency.

Contact Email

info@ctap-duchenne.org

Diversity Spotlight

Women Founded

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

cTAP Platform

A collaborative platform that enables stakeholders to share and analyze de-identified patient data to improve clinical trial design and drug development for Duchenne muscular dystrophy.

Biostatistical Analytics

Tools and methods used to analyze patient data, identify prognostic factors, and enhance clinical trial design by understanding disease progression in Duchenne muscular dystrophy.